Lantheus Holdings Inc

LNTH

Healthcare|Drug Manufacturers - Specialty & Generic|USA

$105.64

-0.34 (-0.32%)

DCF (FCF)

$69.11

Tangible Book

$4.10

Graham Number

$22.41

Earnings Power

$25.99

Upcoming Data Readouts (11)

Aug 2026

Est. completion

Atherosclerosis

Carotid Intraplaque Neovascularization Combined With Stress Echo

NCT05416385n=1,500

Sep 2026

Est. completion

P4Prostate Cancer

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

NCT06074510n=274

Sep 2026

Est. completion

P1Cardiac Amyloidosis

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

NCT06790394n=15

Dec 2026

Est. completion

Sudden Cardiac Arrest

Prediction of ARrhythmic Events With Positron Emission Tomography II

NCT03493516n=302

Jan 2027

Est. completion

Pituitary Adenoma

Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors

NCT07335315n=110

Feb 2027

Est. completion

P1Pancreatic Cancer

A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer

NCT05394259n=36

Mar 2027

Est. completion

P1Head and Neck Cancer

Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer

NCT07501650n=6

Jun 2027

Est. completion

P3Alzheimer Disease

[18F]PI-2620 Phase 3 Histopathological Study

NCT05641688n=200

Aug 2027